title: [Clinical observation of icotinib hydrochloride in first-line therapy for pulmonary adenocarcinoma].
abstract: OBJECTIVE
  It has been proven that icotinib hydrochloride, as a molecule targeted drug, can be safely and efficiently used to treat advanced non-small cell lung cancer (NSCLC) for second-line or third-line. This research was aimed to investigate the efficacy and toxicity of icotinib hydrochloride as the first-line therapy for pulmonary adenocarcinoma.
  
  
  RESULTS
  Among the 56 patients, the tumor objective response rate (ORR) and disease control rate (DCR) was 46.4% (26/56) and 78.6% (46/56), respectively. Among the 20 patients with EGFR analyses, 18 patients were positive for a mutation, ORR was 66.7% (12/18), DCR was 94.4% (17/18) respectively. The ORR with no history of smoke. EGFR positive mutation and appearance of rash were significantly higher than those with smoker, wild type EGFR, no information about EGFR and no appearance of rash (P<0.05). The most common drug-related adverse events were mild skin rash (28.5%) and diarrhea (12%).
  
  
  CONCLUSIONS
  Single agent treatment with icotinib hydrochloride is effective and tolerable in first-line therapy for pulmonary adenocarcinoma, especially with EGFR mutation.
authors.affiliation: Department of Medical Oncology, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing 101149, China.
authors.forename: Xinjie
authors.initials: X
authors.lastname: Yang
authors.forename: Hui
authors.initials: H
authors.lastname: Zhang
authors.forename: Na
authors.initials: N
authors.lastname: Qin
authors.forename: Xi
authors.initials: X
authors.lastname: Li
authors.forename: Jingying
authors.initials: J
authors.lastname: Nong
authors.forename: Jialin
authors.initials: J
authors.lastname: Lv
authors.forename: Yuhua
authors.initials: Y
authors.lastname: Wu
authors.forename: Quan
authors.initials: Q
authors.lastname: Zhang
authors.forename: Shucai
authors.initials: S
authors.lastname: Zhang
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D043844:Crown Ethers / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011799:Quinazolines / Q000009:adverse effects / Q000627:therapeutic use*; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D043844:Crown Ethers; D011799:Quinazolines; C531470:icotinib